PharmaEssentia Corporation, a global biopharmaceutical company headquartered in Taiwan, has signed an investment agreement for a new manufacturing facility in Toa Baja, Puerto Rico.

The signing marks a milestone in the company’s strategy to establish a dual-site manufacturing network in Taiwan and the United States, strengthening global supply chain resilience and supporting long-term growth.

The signing ceremony was attended by Puerto Rico Governor Jenniffer González Colón, Secretary of Economic Development and Commerce Sebastián Negrón Reichard, U.S. Department of Commerce Director for Puerto Rico and the U.S. Virgin Islands Jose Burgos, Director General of the Taipei Economic and Cultural Office (TECO) in Miami Chi Yu Chou, Director of Economic Development of the Municipality of Toa Baja James Ramos, and CEO of Invest Puerto Rico Ella Woger-Nieves, among other distinguished officials.

The Puerto Rico facility is designed to the same high-quality standards of PharmaEssentia’s existing manufacturing site in Taichung, Taiwan, while optimizing production efficiency and diversifying manufacturing risk. Personnel from the Puerto Rico facility will complete intensive training at the Taichung site to support knowledge transfer and operational readiness. The company is planning for the facility to begin operations in 2027 and is committed to engaging with regulators to obtain all necessary approvals.

“Expanding manufacturing capacity outside Taiwan is a core strategic priority for PharmaEssentia,” said Dr. Ko-Chung Lin, Founder and CEO. “We are proud to establish U.S.-based manufacturing, with Puerto Rico serving as a key hub to support the U.S. market and our commitment to patients worldwide – including those benefiting from BESREMi (ropeginterferon alfa-2b-njft).”

More Puerto Rico News

Eli Lilly and Company recently announced plans to invest more than $1.2 billion to expand and modernize its Lilly del Caribe manufacturing site in Carolina, Puerto Rico.